Leica Biosystems and Bio-Techne announce the US launch of RNAscope in situ hybridization automation on the BOND-PRIME staining platform.
Article excerpt
Highlighted: the sentence this signal was extracted from
Leica Biosystems and Bio-Techne announce the US launch of RNAscope in situ hybridization automation on the BOND-PRIME staining platform. The collaboration between Leica Biosystems and Bio-Techne expands access to advanced RNA ISH technology for clinical laboratories across the United States Leica Biosystems Leica Biosystems, a Danaher company and a global leader in anatomic pathology solutions, and Bio-Techne (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, announce the US launch of BOND-PRIME RNAscope Brown Detection, enabling automation of RNAscope(TM) in situ hybridization (ISH) on the BOND-PRIME IHC/ISH staining platform. This combination brings together Bio-Techne's industry-leading RNAscope technology with the speed of the BOND-PRIME platform from Leica Biosystems, empowering pathologists with access to deeper molecular understanding and enhancing laboratory efficiency. As anatomic pathology laboratories face pressure to deliver timely results, the RNAscope workflow on the BOND-PRIME provides RNA detection with full spatial and morphological context, automated on a flexible platform built for high-throughput laboratories. RNAscope can run in less than 8 hours, enabling laboratories to achieve rapid turnaround times without compromising staining quality. This integration brings together Bio-Techne's proven RNA ISH...
Keep reading with a free account
The rest of this article, and every signal for Bio-Techne, is in your free account.
